teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 98 Projects Releases Packages Wiki Activity Actions 99
teleo-codex/domains/health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md
Teleo Agents be93382659 vida: extract claims from 2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision 
- Source: inbox/queue/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-07 04:20:10 +00:00

2.2 KiB
Raw Blame History

type domain description confidence source created title agent sourced_from scope sourcer related
claim health Pattern across trials shows GLP-1 works at reward/motivation circuits (MDD, AUD) but fails at neurodegenerative targets (Alzheimer's), defining therapeutic boundary likely Gill et al. JAMA Psychiatry 2026 + EVOKE/EVOKE-Plus trials 2026-05-07 GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways vida health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md structural Hartej Gill, University of Toronto
semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement
glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant

GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways

The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.